Study shows clinical benefit of a new way of treating advanced ER+ breast cancer


A study in The Lancet Oncology shows that the drug enobosarm has anti-tumor effects in estrogen receptor-positive breast cancer patients. It is the first clinical proof that this can lead to clinical benefit. For at least 40 years, treatment of this type of breast cancer has focused on directly targeting and inhibiting the activity of the estrogen receptor. This new study, therefore, tested a completely different approach using the selective androgen receptor modulator. The drug was found to have anti-tumor effects and was well tolerated with no significant impact on quality of life. This supports further development and assessment of enobosarm and other agents for the treatment of advanced breast cancer.

Source link

error: Content is protected !!